VirtualCareFinder may earn a commission when you visit a provider through our links.
Two Paths to GLP-1 Treatment
Patients pursuing GLP-1 medications for weight management face a fundamental choice: FDA-approved brand-name medications like Wegovy and Zepbound, or compounded versions of semaglutide and tirzepatide prepared by compounding pharmacies. The two options differ meaningfully in safety profile, cost, regulatory status, and availability.
This guide explains the differences factually so you can have an informed conversation with your healthcare provider.
What Are FDA-Approved GLP-1 Medications?
FDA-approved GLP-1 receptor agonists for weight management include:
- Wegovy (semaglutide) — manufactured by Novo Nordisk, FDA-approved for chronic weight management in 2021
- Zepbound (tirzepatide) — manufactured by Eli Lilly, FDA-approved for chronic weight management in 2023
These medications went through extensive clinical trials involving thousands of patients over multiple years. The FDA reviewed their safety data, manufacturing processes, and efficacy before granting approval. Each batch is produced under strictly controlled manufacturing conditions (known as Current Good Manufacturing Practices or cGMP) and is subject to ongoing FDA oversight.
Other GLP-1 medications like Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not weight management. When prescribed for weight loss, they are being used off-label.
What You Get With FDA-Approved Medications
- Clinical trial data from thousands of patients documenting efficacy and side effects
- Consistent manufacturing under cGMP standards
- FDA post-market surveillance monitoring for safety signals
- Established dosing protocols tested in controlled settings
- Insurance coverage potential (with prior authorization)
- Known drug interaction profiles
What Are Compounded GLP-1 Medications?
Compounded semaglutide and tirzepatide are versions of the same active ingredients prepared by compounding pharmacies. These pharmacies combine active pharmaceutical ingredients (APIs) with other components to create the injectable medication.
The Legal Basis for Compounding
Under federal law, compounding pharmacies can produce copies of FDA-approved drugs under specific circumstances. The most relevant to GLP-1 medications is the drug shortage provision: when the FDA designates a drug as being in shortage, compounding pharmacies can legally produce it.
Both semaglutide and tirzepatide have been subject to FDA shortage designations due to the massive demand surge that outpaced manufacturing capacity. As long as these shortage designations are active, compounding is legally permitted.
The critical question is what happens when the shortage ends. If the FDA lifts the shortage designation, the legal basis for compounding these specific medications changes. This has been an evolving situation — the FDA briefly moved to end the semaglutide shortage designation in late 2024, then faced legal challenges. As of early 2026, the regulatory landscape remains fluid.
What You Get With Compounded Medications
- Lower cost (typically $79 to $299 per month versus $800 to $1,300 for brand-name)
- Faster access without insurance prior authorization
- The same active pharmaceutical ingredient (semaglutide or tirzepatide)
- Preparation by licensed pharmacies under state board oversight
What You Do Not Get
- Clinical trial data specific to the compounded formulation
- cGMP manufacturing standards (compounding pharmacies follow USP 797/800 standards, which are different)
- FDA post-market surveillance of the specific product
- Guaranteed long-term availability if shortage designations change
- Insurance coverage (compounded medications are almost always cash-pay)
Safety Considerations
Manufacturing Quality
The core safety difference between compounded and FDA-approved GLP-1 medications is manufacturing oversight.
FDA-approved manufacturers operate under cGMP regulations with regular FDA inspections, batch testing, and documented quality controls. Every vial of Wegovy or Zepbound is produced in the same controlled environment and tested for purity, potency, and sterility.
Compounding pharmacies operate under state pharmacy board oversight and follow USP 797 (sterile compounding) and USP 800 (hazardous drug handling) standards. Quality varies between pharmacies. Some compounding pharmacies operate at a level close to pharmaceutical manufacturers. Others have less rigorous quality controls.
The FDA has issued warning letters to some compounding pharmacies producing GLP-1 medications for quality concerns, including sterility issues and potency discrepancies. This does not mean all compounded GLP-1s are unsafe, but it does mean the quality floor is lower than for FDA-approved products.
Formulation Differences
Compounded GLP-1 medications may differ from brand-name versions in ways beyond the active ingredient:
- Different inactive ingredients. Compounded formulations may use different buffers, preservatives, or carriers.
- Different concentrations. Compounded versions may be prepared at concentrations that differ from the FDA-approved dosing.
- Different delivery devices. Instead of the proprietary autoinjectors used by Wegovy or Zepbound, compounded medications typically come in standard vials with syringes.
Side Effects
The expected side effects of GLP-1 medications — nausea, vomiting, diarrhea, constipation, and injection site reactions — are similar for both compounded and FDA-approved versions, since the active ingredient is the same. However, formulation differences in compounded versions could theoretically affect the side effect profile.
Cost Comparison
| Factor | FDA-Approved (Brand-Name) | Compounded |
|---|---|---|
| Monthly cost without insurance | $800-$1,300 | $79-$299 |
| Monthly cost with insurance | $25-$150 (copay) | Not typically covered |
| Annual cost without insurance | $9,600-$15,600 | $948-$3,588 |
| Annual cost with insurance | $300-$1,800 | Not typically covered |
| Prior authorization required | Yes (for insurance) | No |
| Savings program availability | Yes (manufacturer coupons) | No |
The cost difference is dramatic. For patients without insurance coverage, compounded GLP-1s cost roughly 75% to 90% less than brand-name versions. This cost differential is the primary driver of the compounded GLP-1 market.
Which Telehealth Providers Offer Which
Providers Offering Only FDA-Approved Brand-Name GLP-1s
- Calibrate — Prescribes Wegovy, Zepbound, Mounjaro, and Ozempic exclusively. Works with insurance and handles prior authorizations. Does not offer compounded alternatives.
Providers Offering Compounded GLP-1s (and Sometimes Brand-Name)
- Hims & Hers — Primarily compounded semaglutide and tirzepatide. Cash-pay model.
- Ro — Both compounded semaglutide (cash-pay) and brand-name GLP-1s (through insurance). Offers flexibility to start with compounded while pursuing insurance coverage for brand-name.
- Found — Both compounded and brand-name options. Assists with insurance for brand-name prescriptions.
- Mochi Health — Both compounded and brand-name. Insurance support for brand-name; cash-pay for compounded.
- WW Clinic — Compounded semaglutide available; some brand-name access depending on insurance.
Compare GLP-1 telehealth providers on VirtualCareFinder
How to Evaluate Compounding Pharmacy Quality
If you choose a compounded GLP-1 medication, the quality of the compounding pharmacy matters significantly. Here is what to look for:
Accreditation. Pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or similar organizations have undergone voluntary quality audits.
State licensing. Verify the pharmacy is licensed in your state. State pharmacy boards maintain public databases.
Third-party testing. Some pharmacies conduct independent potency and sterility testing and share results. Ask whether the pharmacy tests every batch.
FDA inspection history. Check the FDA's inspection database for any warning letters or enforcement actions against the pharmacy.
The telehealth platform's vetting process. Ask your telehealth provider how they selected their compounding pharmacy partner and what quality standards they require.
The Regulatory Outlook
The regulatory future of compounded GLP-1 medications is uncertain. Key factors to watch:
FDA shortage designations. As Novo Nordisk and Eli Lilly ramp up manufacturing capacity, shortage designations may be revised or lifted. This would directly affect the legal basis for compounding.
Legal challenges. Multiple lawsuits have been filed regarding the FDA's authority to restrict compounding. Court decisions will shape the market.
State-level regulation. Some states are implementing additional oversight of compounded GLP-1 medications, including testing requirements and labeling rules.
Congressional activity. Legislation has been proposed addressing both compounding regulations and drug pricing for GLP-1 medications.
Patients using compounded GLP-1 medications should be aware that availability could change based on these regulatory developments.
Making Your Decision
The choice between compounded and FDA-approved GLP-1 medications involves tradeoffs that are ultimately personal and medical.
Consider FDA-approved brand-name medications if:
- Your insurance covers them (making cost comparable to compounded)
- You prioritize the established safety and efficacy data from clinical trials
- You want the consistency of cGMP-manufactured products
- Long-term availability certainty matters to you
Consider compounded medications if:
- Insurance does not cover brand-name options and cost is a barrier
- You understand and accept the different risk profile
- Your provider has vetted the compounding pharmacy and is comfortable with the quality
- You are aware that availability may change with regulatory shifts
Regardless of your choice:
- Discuss the decision with your healthcare provider
- Do not adjust dosing on your own
- Report side effects to your provider promptly
- Understand the long-term plan for your treatment
Explore GLP-1 Providers
Browse GLP-1 telehealth providers on VirtualCareFinder to compare which platforms offer brand-name versus compounded medications, their pricing, and their insurance support.